Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BTIG Stick to Their Buy Rating for Axsome Therapeutics Inc

Published 05/11/2021, 06:17 AM
Updated 05/11/2021, 06:17 AM


BTIG analyst Robert Hazlett maintained a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Monday, setting a price target of $123, which is approximately 126.14% above the present share price of $54.39.

Hazlett expects Axsome Therapeutics Inc to post earnings per share (EPS) of -$0.78 for the second quarter of 2021.

The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Axsome Therapeutics, with an average price target of $139.8.
The analysts price targets range from a high of $225 to a low of $104.

In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$27.69 million. The company's market cap is $2.04 billion.

According to TipRanks.com, BTIG analyst Robert Hazlett is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 26.8% and a 43.33% success rate.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.